Abstract: A semiconductor device includes a magnetic tunneling junction (MTJ) on a substrate, a first spacer on a first sidewall of the MTJ, and a second spacer on a second sidewall of the MTJ. Preferably, the first spacer and the second spacer are asymmetric, the first spacer and the second spacer have different heights, and a top surface of the MTJ includes a reverse V-shape.

Abstract: A semiconductor device includes a magnetic tunneling junction (MTJ) on a substrate, a spacer adjacent to the MTJ, a liner adjacent to the spacer, and a first metal interconnection on the MTJ. Preferably, the first metal interconnection includes protrusions adjacent to two sides of the MTJ and a bottom surface of the protrusions contact the liner directly.

Abstract: A charging module configured to charge a plurality of electric vehicles through a plurality of charging piles is provided. The charging module includes a charging prediction mode and a charging scheduling unit. The charging prediction mode is obtained according to a plurality of historical charging data, wherein each historical charging data includes an actual charging amount and at least one of a stay time and a charging time. The charging scheduling unit is configured to obtain a predicted electricity demand and a predicted stay period of each electric vehicle through the charging prediction model; and generate a charging schedule including: providing each electric vehicle with a basic charging amount; and determining a charging priority of the electric vehicles according to the predicted electricity demand and the predicted stay period.

Abstract: Disclosed herein are polypeptides comprising an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-84, 138-146, and 167-184, nanoparticles thereof, related nanoparticle compositions, and their use to treat or limit development of an infection.

Abstract: Polypeptides are disclosed herein having significantly improved secretion ability from eukaryotic cells, together with fusion proteins, nanoparticles, and uses thereof, and methods for designing such polypeptides.

Abstract: A padlock device includes a housing; a shackle associated within the housing and having, with respect to the housing, a closed configuration and an open configuration; a latch subsystem associated with the housing for securely retaining the shackle in the closed configuration, the latch subsystem electrically operable to release the shackle; a biometric sensor associated with the housing to electronically sense fingerprint data from a finger being sensed; a control subsystem in the housing in communication with the biometric sensor and the latch subsystem, the control subsystem comprising: internal processor-readable memory configured to store one or more fingerprint records, each fingerprint record comprising authorized fingerprint data associated with a respective fingerprint identifier; processing structure configured to receive sensed fingerprint data from the biometric sensor and to cause the latch subsystem to release the shackle in the event of a release condition requiring at least that the sensed fin

Abstract: Nanoparticles and vaccines containing these nano particles that elicit an immune response against hemagglutinin (HA) proteins from a broad range of influenza viruses are provided. The nanoparticles are made from self-assembling proteins, at least one of which is joined to an immunogenic portion of an influenza HA protein. This immunogenic portion is displayed on the nanoparticle surface, making the nanoparticles useful for vaccinating subjects against influenza virus.

Abstract: A padlock device includes a housing; a shackle associated within the housing and having, with respect to the housing, a closed configuration and an open configuration; a latch subsystem associated with the housing for securely retaining the shackle in the closed configuration, the latch subsystem electrically operable to release the shackle; a biometric sensor associated with the housing to electronically sense fingerprint data from a finger being sensed; a control subsystem in the housing in communication with the biometric sensor and the latch subsystem, the control subsystem comprising: internal processor-readable memory configured to store one or more fingerprint records, each fingerprint record comprising authorized fingerprint data associated with a respective fingerprint identifier; processing structure configured to receive sensed fingerprint data from the biometric sensor and to cause the latch subsystem to release the shackle in the event of a release condition requiring at least that the sensed fin

Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

Abstract: An industrially scalable two-step process for preparing a ?-L-2?-deoxy-nucleoside that results in a predominance of the ?- over the ?-anomeric form of the compound is described. An optional third step may be used to prepare 3?-prodrugs of desirable ?-L-2?-deoxy-nucleosides for the delivery of these pharmaceuticals effective for treating viral diseases. The synthetic process is applicable in particular to the formation of ?-L-2?-deoxy-cytidine, a pharmaceutically acceptable salt or prodrug thereof. The process can provide a relatively uncontaminated product that may require no further isolation or purification, thereby making the synthesis easily scalable for industrial manufacture.

Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.